Tagged with Generics

Spain Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate managers, and the heads of some of the country’s leading domestic firms. These interviewees’ insights are catalogued in the downloadable…

Italy While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit of innovation. On the contrary, the Italian life science scene is increasingly strong when it comes to behind-the-scenes, incremental innovation.…

India Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA troubles.   Indian pharma market growth in August 12.1 percent (The Economic Times India) According to a study from the…

Global After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part of a broader paring down strategy. For Novartis, the separation of Sandoz would further support our strategy of building a…

Italy EG STADA’s General Manager & Managing Director Italy, Salvatore Butti, explains the company’s strong heritage in generics, the solid presence it is developing in consumer healthcare with new acquisitions from GSK and Sanofi, and its biosimilar and specialties market inroads.  In addition, he tells us about the STADA Health Report,…

USA US generics giant Mallinckrodt, which declared bankruptcy in 2020 after a stream of litigation regarding its role in the opioid epidemic and underpaying Medicaid rebates for its drug Acthar, has announced a new strategic plan and CEO as it emerges from its “restructuring process.”   Controversy on Controversy The USA’s…

Spain João Madeira, General Manager of Viatris Spain discusses the position of the Spanish affiliate and the challenges of a generous decentralised healthcare system. He also outlines some of Viatris’ successes in Spain, such as being the first company to launch an HIV selfdiagnostic test there. … price erosion is such…

Italy Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic products. Aristo differentiates itself in the market through its dynamism and its ability to move quickly and diversify its business…

Europe Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous Tender (MEAT) concept. He also discusses the company’s move towards digitalisation and its ambition to build a bridge between the…

AAM Dan Leonard, President and CEO of the Association for Accessible Medicines (AAM) and Erik C. Komendant, the organisation’s Senior Vice President of Government Affairs, spoke to us about drug pricing issues in the United States and where the AAM stands with respect to the Biden administration’s initiatives to make medicines…

Europe The new president of Medicines for Europe, Elisabeth Stampa, outlines one of the priorities of her mandate: working to adjust the EU pharma policy framework to improve access for patients across Europe.    Regulatory flexibilities implemented during COVID-19 showed that the EU system can require one of highest safety, quality…

Global The Israeli giant began as a wholesale drug business more than a century ago and went on to dominate the global generics market until it lost its leadership position in 2021. After the setbacks of a costly acquisition and several reputational challenges, Teva is pushing to stay on track. Teva…